Remove 2028 Remove Compounding Remove Vaccines
article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108
article thumbnail

ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer

Pharmacy Times

months versus 2.1 months versus 2.1 The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

The FDA Law Blog

CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. covered insulin product or vaccine). A “specified drug” means, for 2021, an applicable drug that is produced, prepared, propagated, compounded, converted, or processed by a specified manufacturer. Final Guidance at 2.

Labelling 105
article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

This high compound annual growth rate of 23.6% These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.